Launched by Eli Lilly in late 2023, Zepbound combines GLP-1 and GIP receptor agonism to deliver superior weight loss compared to single agonists
I use relatively low doses
A fair comparison would require mazdutide to be tested against semaglutide 2.4 mg, which has not happened yet
GLP-1 exerts its effects through several key mechanisms: Glucose-dependent insulin secretion : GLP-1 stimulates pancreatic beta cells to release insulin, but only when blood glucose levels are elevated, reducing the risk of hypoglycaemia Glucagon suppression : It inhibits the release of glucagon from pancreatic alpha cells, thereby reducing hepatic glucose production Delayed gastric emptying : GLP-1 slows the rate at which food leaves the stomach, leading to more gradual glucose absorption and increased satiety Appetite regulation : Acting on brain centres, GLP-1 promotes feelings of fullness and reduces food intake Prescription GLP-1 receptor agonists (such as semaglutide, dulaglutide, and liraglutide) are synthetic analogues designed to mimic and enhance these natural effects
What's Missing in Standard Care Most GLP-1 prescribers overlook critical factors for PCOS patients: Proper dosing for hormone balance, not just weight loss : The optimal dose for PCOS may differ from general weight loss protocols
